Mizuho Lowers Doximity (NYSE:DOCS) Price Target to $26.00

Doximity (NYSE:DOCS) had its price target lowered by equities research analysts at Mizuho from $34.00 to $26.00 in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage currently has a “neutral” rating on the stock. Mizuho’s target price indicates a potential upside of 37.38% from the company’s previous close.

DOCS has been the topic of a number of other research reports. Bank of America reduced their target price on Doximity from $56.00 to $47.00 and set a “buy” rating on the stock in a report on Thursday, April 16th. Wells Fargo & Company reissued an “equal weight” rating and issued a $18.00 price target (down from $32.00) on shares of Doximity in a report on Thursday. Truist Financial reissued a “hold” rating and issued a $29.00 price target (down from $37.00) on shares of Doximity in a report on Monday, April 20th. Jefferies Financial Group downgraded Doximity from a “buy” rating to a “hold” rating and cut their price target for the stock from $51.00 to $19.00 in a report on Thursday. Finally, Zacks Research raised Doximity from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $30.62.

Doximity Trading Up 5.1%

NYSE:DOCS opened at $18.93 on Thursday. The business’s 50 day moving average price is $23.94. Doximity has a 52 week low of $17.15 and a 52 week high of $76.51. The company has a market cap of $3.50 billion, a P/E ratio of 19.12, a PEG ratio of 1.28 and a beta of 1.36.

Doximity announced that its board has approved a stock repurchase plan on Thursday, February 5th that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity at Doximity

In related news, insider Siddharth Sitaram sold 2,309 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $25.77, for a total value of $59,502.93. Following the sale, the insider directly owned 89,396 shares in the company, valued at $2,303,734.92. This trade represents a 2.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Scherer Wampler sold 9,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $26.06, for a total value of $234,540.00. Following the completion of the sale, the director owned 19,839 shares in the company, valued at approximately $517,004.34. This represents a 31.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 18,055 shares of company stock worth $456,061. 31.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Doximity

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Doximity by 4.1% during the 4th quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock valued at $588,281,000 after purchasing an additional 518,916 shares during the period. William Blair Investment Management LLC increased its position in shares of Doximity by 11.7% during the 3rd quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock valued at $426,404,000 after purchasing an additional 609,775 shares during the period. Capital World Investors increased its position in shares of Doximity by 5.1% during the 4th quarter. Capital World Investors now owns 5,654,875 shares of the company’s stock valued at $250,398,000 after purchasing an additional 273,444 shares during the period. Franklin Resources Inc. increased its position in shares of Doximity by 6.2% during the 3rd quarter. Franklin Resources Inc. now owns 3,357,505 shares of the company’s stock valued at $245,601,000 after purchasing an additional 194,912 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Doximity by 29.4% during the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock valued at $71,292,000 after purchasing an additional 694,300 shares during the period. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity said revenue still grew year over year, and its earnings call highlighted strong engagement from AI tool adoption, suggesting the platform is gaining traction with physicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
• Positive Sentiment: Doximity announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, which could support longer-term adoption and monetization. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
• Neutral Sentiment: Several articles noted the stock has become technically oversold after a sharp selloff, which could set up a bounce if sentiment improves. Down 25.7% in 4 Weeks, Here’s Why Doximity (DOCS) Looks Ripe for a Turnaround
• Negative Sentiment: Doximity missed quarterly earnings estimates and issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that growth is slowing. Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
• Negative Sentiment: Analysts turned more cautious, with multiple firms cutting price targets or downgrading the stock, including Baird, Wells Fargo, BTIG, JPMorgan, Mizuho, BMO, Needham and Truist. DOCS vs. HIMS: Which Stock Is the Better Value Option?
• Negative Sentiment: Investor caution also increased after insider selling was disclosed, even though it was tied to a pre-arranged 10b5-1 plan and tax withholding. Doximity (NYSE:DOCS) Insider Siddharth Sitaram Sells 2,309 Shares

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.